|  |
| --- |
|  |
| Book Name: | [**Medical Science: Trends and Innovations**](https://www.bookpi.org/bookstore/product/medical-science-trends-and-innovations-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4264** |
| Title of the Manuscript:  | **Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation** |
| Type of the Article | **Book Chapter** |

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | **Due to the contradictory results found regarding the GVHD with use of the drug, the case report adds to existing literature. It aids in knowledge sharing and helps in developing an evidence-based approach. Although, every case may react differently to therapy, the available literature facilitates decision-making.**  |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | **Yes** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **Yes.However, “**Here we report the case of a patient who successfully used nivolumab without any GVHD or other immune-related adverse events for HNSCC after allogeneic bone marrow transplantation because of the Philadelphia chromosome-positive T cell acute lymphoblastic leukemia.” **Can be replaced by ---**Here we report the case of a patient who was successfully treated with nivolumab and did not develop any GVHD or other immune-related adverse events for HNSCC after allogeneic bone marrow transplantation because of the Philadelphia chromosome-positive T cell acute lymphoblastic leukemia. |  |
| **Is the manuscript scientifically, correct? Please write here.**  | **One point needs to be considered-**The case report of successful use of the drug requires further investigation in a larger sample size for inferences to be drawn. |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.****-** | **Yes. However, recent references can be added. Some suggestions-*** Yamakawa N, Umeda M, Yoshii Y, Mitsudo K, Noguchi M, Kusukawa J, Katakura A, Nakayama H, Sasaki M, Noguchi T, Ueda M, Bukawa H, Yagihara K, Horie A, Miyazaki A, Chikazu D, Tomihara K, Mishima K, Otsuru M, Asoda S, Fujiwara S, Ohyama Y, Kurita H, Kawamata H, Fukuda M, Shintani Y, Kobayashi T, Kanno T, Oh-Iwa I, Kawano K, Yamashita Y, Kobayashi W, Ohiro Y, Uzawa K, Ota Y, Kirita T. Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma. Oral Dis. 2024 Mar;30(2):247-258. doi: 10.1111/odi.14471. Epub 2023 Jan 4. PMID: 36519515.
* Macia-Rivas L, Fernandez-Laguna CL, Alvarez-Asteinza C, Maray I, Carbajales-Alvarez M, Lozano-Blazquez A. Real-world Data Study of the Efficacy and Toxicity of Nivolumab *vs*. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population. Anticancer Res. 2023 Apr;43(4):1681-1688. doi: 10.21873/anticanres.16320. PMID: 36974777.
* Fukuzawa S, Yamagata K, Uchida F, Endo M, Sakamoto N, Bukawa H. A Case of Cholangitis as a Nivolumab-Induced Immune-Related Adverse Event in a Patient with Pulmonary Metastasis After Surgery for Oral Cancer. J Maxillofac Oral Surg. 2024 Aug;23(4):979-983. doi: 10.1007/s12663-023-01976-7. Epub 2023 Jul 26. PMID: 39118937; PMCID: PMC11303653.
* Sekido K, Imaue S, Tachinami H, Tomihara K, Naruto N, Yamagishi K, Ikeda A, Fujiwara K, Noguchi M. Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy. Clin Case Rep. 2023 Nov 28;11(12):e8219. doi: 10.1002/ccr3.8219. PMID: 38033699; PMCID: PMC10683031.
 |  |
| Is the language/English quality of the article suitable for scholarly communications? | **Yes** |  |
| Optional/General comments |  |  |

|  |
| --- |
| **PART 2:**  |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  | *(If yes, Kindly please write down the ethical issues here in details)* |  |

|  |
| --- |
| **Reviewer Details:** |
| Name: | **Nilima Prakash** |
| Department, University & Country | **MGV’s KBH Dental College and Hospital, India** |